Natalie Arnold/LinkedIn
Jan 25, 2026, 12:17
Natalie Arnold on 11 Clinical Trials That Will Shape Medicine in 2026
Natalie Arnold, Preventive Cardiologist at University Heart and Vascular Center Hamburg, shared on LinkedIn:
”“What does the coming day hold (for me)?”
(AS Pushkin, Eugene Onegin)
Nature Medicine recently spotlighted 11 clinical trials that may shape medicine in 2026.
Two of them align directly with my research focus in cardiovascular prevention:
• Low-grade inflammation: IL-6 inhibition with ziltivekimab
• Lipoprotein (a): pelacarsen for patients with elevated Lp(a)
2026 may be a key year for turning “residual risk” biology into therapies that improve clinical outcomes.”
Read the full article here.
Article: Eleven clinical trials that will shape medicine in 2026
Author: Mike May
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?
-
Sep 30, 2026, 13:03Amira Mohy: Diagnostic Flow Cytometry Panels for Hematological Malignancies
-
Sep 30, 2026, 12:52Paul Watton: Could Repetitive Head Impacts Leave a Molecular Memory?
-
Sep 30, 2026, 12:41The Journey to ISTH 2027 Starts in Vancouver